Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0200 • ACR Convergence 2022
Should Independence Play a Role in Assessing Remission in Rheumatoid Arthritis?
Thomas Khoo¹, Bethan Jones², Athena Chin¹, Alice Terrett³, Marieke Voshaar⁴, Wijnanda Hoogland⁵, Lyn March⁶, Dorcas Beaton⁷, Ummugulsum Gazel⁸, Beverley Shea⁹, Peter Tugwell¹⁰, Caroline Flurey¹¹ and Susanna Proudman¹², ¹Rheumatology Unit, Flinders Medical Centre, Adelaide, Australia, ²School of Healthcare and Social Wellbeing, University of the West of England, Bristol, United Kingdom, ³Rheumatology Unit, The Royal Adelaide Hospital, Adelaide, Australia, ⁴Department of Pharmacy and Department of Research & Innovation, Sint Maartenskliniek and Department of Pharmacy, Radboud University Medical Centre, Nijmegan, Netherlands, ⁵OMERACT Patient Research Partner, Netherlands, ⁶Sydney Medical School, Institute of Bone and Joint Research, and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia, ⁷Institute for Work & Health, Toronto, ON, Canada, ⁸University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, ON, Canada, ⁹School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada, Ottawa, Canada, ¹⁰University of Ottawa, Ottawa, Canada, Ottawa, ON, Canada, ¹¹Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ¹²Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide, Adelaide, Australia
Background/Purpose: The current goal of treatment in rheumatoid arthritis (RA) is clinical remission, which according to the ACR/EULAR 2011 definition, is based on tender and…
Abstract Number: 0251 • ACR Convergence 2022
Nuclear Factor of Activated T Cells Cytoplasmic 1 as a Potential Biomarker of Increased Cardiovascular Risk in Patients with Early Rheumatoid Arthritis
Sara Remuzgo-Martinez¹, Fernanda Genre¹, Veronica Pulito-Cueto², Alfonso Corrales¹, Virgi Portilla¹, Leticia Lera-Gómez¹, Belén Atienza-Mateo¹, María Sebastián Mora-Gil¹, J Gonzalo Ocejo-Vinyals³, Oreste Gualillo⁴, Ricardo Blanco⁵, Ivan Ferraz Amaro⁶, Santos Castañeda⁷, Raquel Lopez Mejias² and Miguel Ángel González-Gay⁸, ¹Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²IDIVAL, Santander, Spain, ³Department of Immunology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Hospital Clínico Universitario de Santiago, SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago de Compostela, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁶Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ⁷Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁸Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: NFKB1, NKIRAS1, NFATc1, NFATc2 and MTHFR, inflammation and immune response-related genes, predispose to the increased risk of cardiovascular (CV) disease in patients with RA…
Abstract Number: 0267 • ACR Convergence 2022
Cancer Risk with Biologic and Targeted Synthetic DMARDs in Patients with Rheumatic Diseases and Previous Malignancy: Results from the BIOBADASER Register
Juan Molina¹, Fernando Sanchez-Alonso², Cristina Bohorquez³, Cesar Diaz-Torne⁴, Carolina Perez-Garcia⁵, Juan Maria Blanco-Madrigal⁶, Paloma Vela-Casampere⁷, José María Älvaro-Gracia¹ and Isabel Castrejon⁸, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, ³University Hospital Príncipe de Asturias, Immune System Diseases-Rheumatology Service, Alcalá de Henares, Madrid, Spain, ⁴Department of Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁵Department of Rheumatology, Hospital del Mar, Barcelona, Spain, ⁶Department of Rheumatology, Hospital de Basurto, Bilbao, Spain, ⁷Hospital General Universitario Alicante, Alicante, Spain, ⁸Hospital Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: To investigate the occurrence and relative risk of incident malignancy in patients with rheumatic diseases and previous malignancy treated with biologic and targeted synthetic…
Abstract Number: 0285 • ACR Convergence 2022
Characteristics and Outcomes of Patients with Rheumatoid Arthritis Treated with Upadacitinib in a Global Real-World Setting
Roberto Felice Caporali¹, Jayeshkumar Patel², Oliver Howell³, sander strengholt⁴, Hannah Jones³ and Peter Taylor⁵, ¹University of Milan, Milano, Italy, ²AbbVie, Inc., North Chicago, IL, ³Adelphi Real World, Bollington, United Kingdom, ⁴AbbVie, Inc., Abcoude, Netherlands, ⁵University of Oxford, Oxford, United Kingdom
Background/Purpose: Upadacitinib (UPA), a Janus kinase inhibitor, is a newly approved advanced therapy for patients (pts) with rheumatoid arthritis (RA), thus real-world evidence is lacking.…
Abstract Number: 0301 • ACR Convergence 2022
Effectiveness and Safety of Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: Third Interim Analysis of a German Non-Interventional, Prospective, Multicenter Study (ESCALATE-RA)
Klaus Krüger¹, Ulrich Prothmann², Thilo Klopsch³, Olaf Behmer⁴, Min-Jean Hsieh⁴, Jürgen Jobst⁴, Pascal Klaus⁴ and Thomas Meng⁴, ¹Praxiszentrum St. Bonifatius, Rheumatology, München, Germany, ²Knappschaftsklinikum Saar, Püttlingen, Germany, ³Rheumatological Practice, Neubrandenburg, Germany, ⁴Pfizer Pharma GmbH, Berlin, Germany
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. ESCALATE-RA is the first prospective, non-interventional study with tofacitinib in Germany.Methods:…
Abstract Number: 0499 • ACR Convergence 2022
Drivers of Heterogeneity in Synovial Fibroblasts in Rheumatoid Arthritis
Melanie Smith¹, Vianne Gao², Edward DiCarlo¹, Susan Goodman¹, Thomas Norman², Laura Donlin¹, Christina Leslie² and Alexander Rudensky², ¹Hospital for Special Surgery, New York, NY, ²Memorial Sloan Kettering Cancer Center, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is characterized by hyperplasia of both the synovial lining, which forms the synovial fluid interface, as well as the synovial sublining,…
Abstract Number: 0565 • ACR Convergence 2022
Deciphering Complement System-dependent Cellular Pathways in Human Rheumatoid Arthritis Synovial Tissues Using Single-cell Computational Omics
Juan Vargas¹, Nirmal Banda², Ian Mantel³, Anna Jonsson⁴, Kevin Wei⁵, Deepak Rao⁴, Susan Goodman⁶, Kevin D Deane⁷, Jennifer Seifert⁸, Jennifer Anolik⁹, Michael Brenner¹⁰, Soumya Raychaudhuri⁴, Accelerating Medicines Partnership RA/SLE⁴, Michael Holers², Laura Donlin⁶ and Fan Zhang⁸, ¹School Public Health Biostatistics Department, Aurora, CO, ²Department of Medicine Division of Rheumatology, Aurora, CO, ³Weill Cornell Medicine, New York, NY, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Hospital for Special Surgery, New York, NY, ⁷University of Colorado Denver Anschutz Medical Campus, Denver, CO, ⁸University of Colorado, Aurora, CO, ⁹University of Rochester Medical Center, Rochester, NY, ¹⁰Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The complement system is a major component of innate immunity and plays a vital role in experimental models of autoimmune arthritis pathogenesis. In patients…
Abstract Number: 0599 • ACR Convergence 2022
Expansion of HLA-DR+CD45RAhi Non-lymphoid Cells in Patients with Rheumatoid Arthritis
Christian Geier¹, Andras Perl² and Robert Winchester³, ¹SUNY Upstate Medical University, Syracuse, NY, ²SUNY, Syracuse, NY, ³Columbia University, New York, NY
Background/Purpose: In RA, aberrant lymphocytes can damage synovial joints and other organs. Antigen-presenting cells (APC) can activate lymphocytes and are considered critical to initiate immune…
Abstract Number: 0617 • ACR Convergence 2022
Killer Cell Immunoglobulin Receptor and Class I HLA Genetic Variability in South-eastern Spanish Rheumatoid Arthritis Patients
Pablo Mesa-del-Castillo B.¹, Lourdes Gimeno Arias¹, Jose Miguel Bolarin², Luis Francisco Linares Ferrando¹, Alfredo Minguela-Puras¹ and Carlos Marras Fernández Cid¹, ¹Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²IT Tecnological Center (CENTIC), Murcia, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a common chronic inflammatory disorder characterized by bone erosions and progressive joint destruction. Genetic, epigenetic and environmental factors may induce…
Abstract Number: 0715 • ACR Convergence 2022
Safety and Immunogenicity of Mixed COVID19 Vaccine Regimens in Immune-mediated Inflammatory Diseases: An Observational Cohort
Carol Hitchon¹, Christine Mesa², Charles N Bernstein¹, Catherine Card², RuthAnn Marrie¹, Sheila O'Brien³ and John Kim², ¹University of Manitoba, Winnipeg, MB, Canada, ²Public Health Agency of Canada, Winnipeg, MB, Canada, ³Canada Blood Services, Ottawa, Canada
Background/Purpose: Data on immunogenicity and safety of COVID-19 vaccination strategies exist for the general population, however, such data are limited for immunocompromised people including those…
Abstract Number: 0782 • ACR Convergence 2022
Low Circulating B Cells Correlate with Unresponsiveness to COVID-19 Vaccination Among Patients Treated with Rituximab
Christopher Halbur¹, Erin Sternhagen², Mohamad Dave Dimachkie² and Petar Lenert², ¹University of Iowa Carver College of Medicine, Iowa City, IA, ²University of Iowa Hospitals and Clinics, Iowa City, IA
Background/Purpose: Rituximab impairs humoral immunity by depleting CD20+ B cells. Previous studies have demonstrated that patients on rituximab have decreased immune response to COVID-19 vaccination.…
Abstract Number: 0889 • ACR Convergence 2022
Serum Adipokines Predict Incident Osteoporotic Fracture in Patients with Rheumatoid Arthritis
Joshua Baker¹, Katherine Wysham², Bryant England³, Punyasha Roul⁴, Aleksander Lenert⁵, Grant Cannon⁶, Brian Sauer⁷, Geoffrey Thiele³ and Ted Mikuls⁸, ¹University of Pennsylvania, Philadelphia, PA, ²VA Puget Sound/University of Washington, Seattle, WA, ³University of Nebraska Medical Center, Omaha, NE, ⁴UNMC, Omaha, NE, ⁵University of Iowa, Iowa City, IA, ⁶Retired, Salt Lake City, UT, ⁷Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁸Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Adipokines are fat and muscle-secreted protein hormones that regulate metabolism. Adiponectin has been associated with fracture in the general population while the role of…
Abstract Number: 0905 • ACR Convergence 2022
Predicting Disease Activity in Rheumatoid Arthritis Patients Using Machine Learning: Data from the ACR’s RISE Registry
Eren-Ajani Tshimanga¹, Milena Gianfrancesco², Stefanos Giampanis³, Jing Li², Emma Kersey⁴, Jinoos Yazdany⁵, Beau Norgeot⁶, Gabriela Schmajuk⁷ and Zara Izadi⁴, ¹University of California, Berkeley, Berkeley, CA, ²University of California, San Francisco, San Francisco, CA, ³Anthem, San Francisco, ⁴University of California San Francisco, San Francisco, CA, ⁵UCSF, San Francisco, CA, ⁶Anthem, Oakland, CA, ⁷UCSF / SFVA, San Francisco, CA
Background/Purpose: Predicting the trajectory of disease in individuals with RA is difficult, with numerous factors influencing whether a patient may experience higher or lower disease…
Abstract Number: 0921 • ACR Convergence 2022
Effects of Methotrexate on the Liver Function and Disease Activity of Newly Diagnosed RA Patients Depending on the Cardiometabolic Profile
Ivan Arias-de la Rosa¹, Miriam Ruiz-Ponce¹, Laura Cuesta-Lopez¹, Rafaela Ortega-Castro¹, Jerusalem Calvo¹, lourdes Ladehesa-Pineda², Carlos Pérez-Sánchez¹, Chary López-Pedrera³, Eduardo Collantes¹, Alejandro Escudero-Contreras¹ and Nuria Barbarroja¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, ³Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain
Background/Purpose: Methotrexate (MTX) is the first-line treatment in Rheumatoid arthritis (RA) patients. To date, the evidence about the liver disease caused by MTX is controversial.…
Abstract Number: 0938 • ACR Convergence 2022
Baseline Predictors of Disease Flare upon csDMARD Withdrawal in Patients with Rheumatoid Arthritis in Sustained Remission After DAS-driven Therapy: Role of the Systemic Autoimmune Status and Peripheral Joint Ultrasound Across a 5-year Follow-up
Antonio Manzo¹, Emanuele Bozzalla Cassione², Iolanda Mazzucchelli³, Silvia Grignaschi³, Blerina Xoxi³, Terenzj Luvaro³, Ludovico De Stefano³, Garifallia Sakellariou³, SERENA BUGATTI³ and Carlomaurizio Montecucco⁴, ¹IRCCS Policlinico San Matteo Foundation/University of Pavia, Pavia, Pavia, Italy, ²University of Pavia, IRCCS Policlinico San Matteo Foundation, Milano, Milan, Italy, ³University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, Pavia, Italy, ⁴Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy
Background/Purpose: Early diagnosis and treat-to-target strategies with synthetic conventional DMARDs in rheumatoid arthritis (RA) have allowed the achievement of remission in a significant percentage of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].